Download PDF
Horm Metab Res 2023; 55(08): 573-579
DOI: 10.1055/a-2065-0954
Original Article: Endocrine Research

Mir-629 Repressed LATS2 Expression and Promoted the Proliferation of Prostate Cancer Cells

Yuqiao Li
1   Department of Urology, Liaocheng People’s Hospital, Liaocheng City, China
,
Sha Zeng
1   Department of Urology, Liaocheng People’s Hospital, Liaocheng City, China
,
Longbin Cao
1   Department of Urology, Liaocheng People’s Hospital, Liaocheng City, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

MicroRNAs (miRNAs) have been discovered to play critical role in regulating prostate cancer (PC) progression. The function role of miR-629 in tumor progression of PC has not been studied. Here, we found that miR-629 was markedly upregulated in PC as determined using the cancer genome atlas (TCGA) dataset, clinical tissues, and cell lines. Functional analysis (MTT assays, colony formation assays, soft agar growth assay and BrdU incorporation assay) indicated that overexpression of miR-629 was drastically promoted, while miR-629-in significantly suppressed cell proliferation. LATS2 was predicted as a direct target of miR-629 and was confirmed by western blot and dual luciferase assay. Through downregulation of large tumor suppressor 2 (LATS2) by overexpression of miR-629, the p21 mRNA and protein were decreased while the Cyclin D3 mRNA and protein were enhanced, suggesting promoting of cell proliferation process. Additionally, knockdown of LATS2 reversed the inhibitory effect by miR-629-in in PC. Our study indicated that miR-629 might serve as a new promising target for PC treatment.

Key words

miR-629 - prostate cancer - cell proliferation - LATS2


Publication History

Received: 05 February 2023

Accepted: 29 March 2023

Accepted Manuscript online:
29 March 2023

Article published online:
28 April 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J Clin 2019; 69: 7-34
    CrossrefPubMedGoogle Scholar
  • 2 Li G, Wu X, Qian W. et al. CCAR1 5’ UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance. Cell Res 2016; 26: 655-673
    CrossrefPubMedGoogle Scholar
  • 3 Zhang CZ, Cao Y, Fu J. et al. miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33. Mol Oncol 2016; 10: 1532-1541
    CrossrefPubMedGoogle Scholar
  • 4 Peng L-N, Deng X-Y, Gan X-X. et al. Targeting of TLE3 by miR-3677 in human breast cancer promotes cell proliferation, migration and invasion. Oncology Lett 2020; 19: 1409-1417
    PubMedGoogle Scholar
  • 5 Selth LA, Das R, Townley SL. et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene 2017; 36: 24-34
    CrossrefPubMedGoogle Scholar
  • 6 Xu S, Ge J, Zhang Z. et al. miR-141 inhibits prostatic cancer cell proliferation and migration, and induces cell apoptosis via targeting of RUNX1. Oncol Rep 2018; 39: 1454-1460
    PubMedGoogle Scholar
  • 7 Cai D, Zhang J, Yang J. et al. Overexpression of FTO alleviates osteoarthritis by regulating the processing of miR-515-5p and the TLR4/MyD88/NF-kappaB axis. Int Immunopharmacol 2023; 114: 109524
    CrossrefPubMedGoogle Scholar
  • 8 He LP, Zhou ZX, Li CP. Narrative review of ferroptosis in obesity. J Cell Mol Med 2023; 27: 920-926
    CrossrefPubMedGoogle Scholar
  • 9 Zhang X, Zhou J, Xue D. et al. MiR-515-5p acts as a tumor suppressor via targeting TRIP13 in prostate cancer. Int J Biol Macromol 2019; 129: 227-232
    CrossrefPubMedGoogle Scholar
  • 10 Tang Y, Pan J, Huang S. et al. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling. J Exp Clin Cancer Res 2018; 37: 160-160
    CrossrefPubMedGoogle Scholar
  • 11 Yu Y, Wang Z, Sun D. et al. miR-671 promotes prostate cancer cell proliferation by targeting tumor suppressor SOX6. Eur J Pharmacol 2018; 823: 65-71
    CrossrefPubMedGoogle Scholar
  • 12 Li B, Meng YQ, Li Z. et al. MiR-629-3p-induced downregulation of SFTPC promotes cell proliferation and predicts poor survival in lung adenocarcinoma. Art Cell Nanomed Biotechnol 2019; 47: 3286-3296
    PubMedGoogle Scholar
  • 13 Tao X, Yang X, Wu K. et al. miR-629-5p promotes growth and metastasis of hepatocellular carcinoma by activating β-catenin. Exp Cell Res 2019; 380: 124-130
    CrossrefPubMedGoogle Scholar
  • 14 Shi W, Lu Y, Gong R. et al. Serum miR-629 is a novel molecular marker for diagnosis and the prognosis of pancreatic cancer. Eur Rev Med Pharmacol Sci 2018; 22: 5187-5193
    PubMedGoogle Scholar
  • 15 Cai C, Chen QB, Han ZD. et al. miR-195 Inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. Clin Cancer Res 2015; 21: 4922-4934
    CrossrefPubMedGoogle Scholar
  • 16 Feliciano A, Garcia-Mayea Y, Jubierre L. et al. miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer. Cell Death Dis 2017; 8: e3141
    CrossrefPubMedGoogle Scholar
  • 17 Hironaka-Mitsuhashi A, Otsuka K, Gailhouste L. et al. MiR-1285-5p/TMEM194A axis affects cell proliferation in breast cancer. Cancer Sci 2020; 111: 395-405
    CrossrefPubMedGoogle Scholar
  • 18 Peng LN, Deng XY, Gan XX. et al. Targeting of TLE3 by miR-3677 in human breast cancer promotes cell proliferation, migration and invasion. Oncology Lett 2020; 19: 1409-1417
    PubMedGoogle Scholar
  • 19 Pan C, He L. Blood lipids are not specific for stroke risk. Biol Trace Elem lRes 2023; 201: 527-528
    CrossrefPubMedGoogle Scholar
  • 20 Ren XH, Pan RJ, Li ZP. et al. The difference in body type may modify the relationship between dietary mineral intake and hypertension among Korean adults. Biol Trace Elem Res 2023; 201: 1670-1671
    CrossrefPubMedGoogle Scholar
  • 21 Shi J, He L. Long-term use of anti-coronary heart disease medications may impact the serum zinc concentration. Biol Trace Elem Res 2023; 201: 1
    CrossrefPubMedGoogle Scholar
  • 22 Wang Y, Pan R, He L. Taking medication for diabetes may modify the link between serum zinc concentrations and prediabetes and diabetes in the general population. Biol Trace Elem Res 2023; 201: 1118-1119
    CrossrefPubMedGoogle Scholar
  • 23 Wang J, Song C, Tang H. et al. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res 2017; 19: 72
    CrossrefPubMedGoogle Scholar
  • 24 Lu J, Lu S, Li J. et al. promotes colorectal cancer progression through targetting CXXC finger protein 4. Biosci Rep 2018; 38
    PubMedGoogle Scholar
  • 25 Yan H, Li Q, Wu J. et al. MiR-629 promotes human pancreatic cancer progression by targeting FOXO3. Cell Death Dis 2017; 8: e3154
    CrossrefPubMedGoogle Scholar
  • 26 Suzuki H, Yabuta N, Okada N. et al. Lats2 phosphorylates p21/CDKN1A after UV irradiation and regulates apoptosis. J Cell Sci 2013; 126: 4358-4368
    CrossrefPubMedGoogle Scholar
  • 27 Furth N, Pateras IS, Rotkopf R. et al. LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state. Life Sci Alliance 2018; 1: e201800171
    CrossrefPubMedGoogle Scholar
  • 28 Wu T, Hu H, Zhang T. et al. miR-25 promotes cell proliferation, migration, and invasion of non-small-cell lung cancer by targeting the LATS2/YAP signaling pathway. Oxid Med Cell Longev 2019; 9719723
    PubMedGoogle Scholar
  • 29 Xie Y, Lv Y, Zhang Y. et al. LATS2 promotes apoptosis in non-small cell lung cancer A549 cells via triggering Mff-dependent mitochondrial fission and activating the JNK signaling pathway. Biomed Pharmacother 2019; 109: 679-e201800689
    CrossrefPubMedGoogle Scholar
  • 30 Kim MH, Yoo S, Choo MS. et al. The role of the serum 25-OH vitamin D level on detecting prostate cancer in men with elevated prostate-specific antigen levels. Sci Rep 2022; 12: 14089
    CrossrefPubMedGoogle Scholar
  • 31 Song YX, He LP, Li CP. The relationship between serum calcium level and risk factor of pregnancy-induced hypertension: a meta-analysis. Clin Exp Obstet Gyn 2023; 50: 66
    CrossrefPubMedGoogle Scholar
  • 32 Hamblen AJ, Bray JW, Hingorani M. et al. Physical activity and dietary considerations for prostate cancer patients: future research directions. Proc Nutr Soc 2023; 1-7
    CrossrefPubMedGoogle Scholar
  • 33 He LP, Song YX, Zhu T. et al. Progress in the relationship between vitamin D deficiency and the incidence of type 1 diabetes mellitus in children. J Diabetes Res 2022; 5953562
    PubMedGoogle Scholar
  • 34 Gomez-Martin A, Martinez-Gonzalez LJ, Puche-Sanz I. et al. GSTM1 gene expression and copy number variation in prostate cancer patients-Effect of chemical exposures and physical activity. Urol Oncol 2019; 37: 290 e299-290 e215
    CrossrefPubMedGoogle Scholar
  • 35 Li C, Liu X, Wang X. et al. Trait creativity, personality, and physical activity: a structural equation model. Ann Palliat Med 2023; 12: 141-149
    CrossrefPubMedGoogle Scholar